Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPHNASDAQ:CVACNASDAQ:MLYSNASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$8.09+1.3%$7.95$5.15▼$10.67$1.09B1.161.33 million shs1.04 million shsCVACCureVac$4.46+0.5%$3.49$2.37▼$5.28$1.00B2.49721,815 shs437,407 shsMLYSMineralys Therapeutics$15.62+0.6%$14.43$8.24▼$18.38$1.02B-0.3500,775 shs415,796 shsTNXPTonix Pharmaceuticals$38.41-1.4%$22.34$6.76▼$485.76$281.35M1.63903,269 shs674,588 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals-0.12%+0.13%-3.27%-2.44%+51.61%CVACCureVac-5.53%0.00%+27.95%+38.75%+9.90%MLYSMineralys Therapeutics-4.08%-2.02%-0.70%+47.25%+19.38%TNXPTonix Pharmaceuticals-3.71%+3.34%+98.93%+166.23%-92.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals3.2605 of 5 stars3.52.00.00.03.41.71.9CVACCureVac4.215 of 5 stars3.52.00.04.83.80.01.3MLYSMineralys Therapeutics2.6995 of 5 stars3.51.00.00.02.75.00.0TNXPTonix Pharmaceuticals3.7583 of 5 stars3.54.00.00.03.23.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 3.00Buy$11.5042.15% UpsideCVACCureVac 3.00Buy$11.00146.64% UpsideMLYSMineralys Therapeutics 3.00Buy$38.00143.28% UpsideTNXPTonix Pharmaceuticals 3.00Buy$585.001,423.04% UpsideCurrent Analyst Ratings BreakdownLatest TNXP, AUPH, CVAC, and MLYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025CVACCureVacJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$10.005/14/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.005/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.004/30/2025CVACCureVacUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$13.00 ➝ $12.004/2/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.00 ➝ $42.003/20/2025TNXPTonix PharmaceuticalsNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.003/10/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$247.30M4.42N/AN/A$2.63 per share3.08CVACCureVac$523.70M1.91N/AN/A$2.50 per share1.78MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ATNXPTonix Pharmaceuticals$10.04M28.02N/AN/A$5,751.80 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals-$78.02M$0.28N/A14.45N/A-10.23%-4.41%-3.07%7/30/2025 (Estimated)CVACCureVac-$281.58M$0.928.11N/AN/A20.72%21.98%15.72%8/13/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.73N/AN/AN/AN/A-67.97%-62.40%8/12/2025 (Estimated)TNXPTonix Pharmaceuticals-$116.66M-$1,963.61N/AN/AN/A-1,197.86%-163.95%-118.88%8/15/2025 (Estimated)Latest TNXP, AUPH, CVAC, and MLYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q1 2025CVACCureVac-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/12/2025Q1 2025MLYSMineralys Therapeutics-$1.02-$0.79+$0.23-$0.79N/AN/A5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23-$2.84+$0.39-$2.84$2.55 million$2.43 million4/10/2025Q4 2024CVACCureVac-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 million3/18/2025Q4 2024TNXPTonix Pharmaceuticals-$6.23-$9.77-$3.54-$9.77$3.20 million$2.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ACVACCureVacN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.175.605.11CVACCureVac0.056.206.19MLYSMineralys TherapeuticsN/A14.0214.02TNXPTonix Pharmaceuticals0.073.332.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%CVACCureVac17.26%MLYSMineralys Therapeutics84.46%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%CVACCureVac2.15%MLYSMineralys Therapeutics25.56%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300135.10 million137.02 millionOptionableCVACCureVac880224.34 million219.07 millionOptionableMLYSMineralys Therapeutics2865.18 million33.27 millionOptionableTNXPTonix Pharmaceuticals507.33 million1.87 millionNot OptionableTNXP, AUPH, CVAC, and MLYS HeadlinesRecent News About These CompaniesTonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025June 5 at 7:00 AM | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 2.8% - What's Next?June 4 at 1:12 PM | marketbeat.comNorthern Trust Corp Acquires New Shares in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)June 4 at 3:02 AM | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 10.4% - Time to Buy?June 3 at 3:12 PM | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 4.1% - What's Next?June 2 at 2:22 PM | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Downgraded by Wall Street Zen to "Sell"June 1, 2025 | americanbankingnews.comZacks Small Cap Issues Optimistic Forecast for TNXP EarningsJune 1, 2025 | americanbankingnews.comTonix Pharmaceuticals (NASDAQ:TNXP) Cut to Sell at Wall Street ZenMay 31, 2025 | marketbeat.comTonix Pharmaceuticals: August PDUFA Date For Fibromyalgia Med A Risky BetMay 30, 2025 | seekingalpha.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 3.6% - Here's WhyMay 30, 2025 | marketbeat.comZacks Small Cap Brokers Boost Earnings Estimates for TNXPMay 30, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 9.1% - Should You Buy?May 29, 2025 | marketbeat.comJane Street Group LLC Purchases 1,635,119 Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)May 29, 2025 | marketbeat.comWhat's Going On With Tonix Pharmaceuticals Stock?May 28, 2025 | benzinga.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 6% - Time to Sell?May 28, 2025 | marketbeat.comTNXP: Preparations Continue for Potential Commercial Launch of TNX-102 SL in Fibromyalgia…May 28, 2025 | finance.yahoo.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 9% - Here's WhyMay 27, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading 2.8% Higher - Still a Buy?May 25, 2025 | marketbeat.comPoint72 Asset Management L.P. Makes New $526,000 Investment in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)May 25, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Upgraded at Wall Street ZenMay 24, 2025 | marketbeat.comTonix Pharmaceuticals CEO Seth Lederman Participates in A.G.P. Annual Healthcare Company ShowcaseMay 22, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNXP, AUPH, CVAC, and MLYS Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$8.09 +0.10 (+1.25%) Closing price 04:00 PM EasternExtended Trading$8.07 -0.02 (-0.19%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.CureVac NASDAQ:CVAC$4.46 +0.02 (+0.45%) Closing price 04:00 PM EasternExtended Trading$4.52 +0.06 (+1.43%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Mineralys Therapeutics NASDAQ:MLYS$15.62 +0.10 (+0.64%) Closing price 04:00 PM EasternExtended Trading$15.62 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Tonix Pharmaceuticals NASDAQ:TNXP$38.41 -0.54 (-1.39%) Closing price 04:00 PM EasternExtended Trading$38.16 -0.25 (-0.65%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
